VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
VBIV was delisted on the 7th of August, 2024.
40 hedge funds and large institutions have $71.2M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
17% less capital invested
Capital invested by funds: $85.3M → $71.2M (-$14.1M)
17% less funds holding
Funds holding: 48 → 40 (-8)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$146K |
| 2 |
Renaissance Technologies
New York
|
+$141K |
| 3 |
Squarepoint
New York
|
+$111K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$82K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$56.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$822K |
| 2 |
Morgan Stanley
New York
|
-$453K |
| 3 |
BHB
Bank Hapoalim BM
Tel Aviv,
Israel
|
-$357K |
| 4 |
Jane Street
New York
|
-$331K |
| 5 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$330K |
VBIV Hedge Fund Activity: Q3 2018 in Review
40 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q3 2018, worth a combined $71.2M — down 17% from $85.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of VBIV and 3 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 9 added.
The largest buyer was Cambridge Investment Research Advisors, adding an estimated $146K. The largest seller was Millennium Management, cutting an estimated $822K.
- 40 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q3 2018, down from 48 in Q2 2018.
- Funds reported $71.2M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q3 2018, down 17% quarter-over-quarter.
- 3 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q3 2018 and 11 closed out, a net change of -8 holders.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q3 2018 was Cambridge Investment Research Advisors, an estimated $146K added.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q3 2018 was Millennium Management, an estimated $822K sold.
Based on aggregated 13F filings for Q3 2018.